RE:RE:RE:RE:RE:RE:RE:RE:correction short-lived?I see, thanks. I thought I missed something that triggered the significant drop and created a new gap.
The fundamentals haven't changed, and based on consolidated earinings multiple, this stock is cheap in the Pharma space (13X?). not to mention, that we can likely expect another billion dollar deal coming shortly. I assume from Europe this time since Thompson, whenever he speaks to the market, seems to let everyone know what to expect. Everything he says means something it seems.